

Genfore version 5.1.3  
Copyright (c) 1993 - 2003 CompuGen Inc.

OM protein - protein search, using sw model

Run on: January 15, 2003, 15:34:17 Search: 11-52 (296 Sequences)  
(without alignments)  
28,011 Million cell updates/sec

Title: us-09-856-070-23

Perfect score: 55

Sequence: 1 ELMRLQPYEE 11

Scoring table: HIGSOM62

Gapop 10 0 Gap-xt 0.5

Searched: 908470 seqs, 13250620 residues

Total number of hits satisfying chosen parameters: 908470

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database: A\_Geneseq\_101002\_\*

- 1: /SID52/qcdata/qcseq/geneseq-emb1/AA1980.DAT\*
- 2: /SID52/qcdata/qcseq/geneseq-emb1/AA1981.DAT\*
- 3: /SID52/qcdata/qcseq/geneseq-emb1/AA1982.DAT\*
- 4: /SID52/qcdata/qcseq/geneseq-emb1/AA1983.DAT\*
- 5: /SID52/qcdata/qcseq/geneseq-emb1/AA1984.DAT\*
- 6: /SID52/qcdata/qcseq/geneseq-emb1/AA1985.DAT\*
- 7: /SID52/qcdata/qcseq/geneseq-emb1/AA1986.DAT\*
- 8: /SID52/qcdata/qcseq/geneseq-emb1/AA1987.DAT\*
- 9: /SID52/qcdata/qcseq/geneseq-emb1/AA1988.DAT\*
- 10: /SID52/qcdata/qcseq/geneseq-emb1/AA1989.DAT\*
- 11: /SID52/qcdata/qcseq/geneseq-emb1/AA1990.DAT\*
- 12: /SID52/qcdata/qcseq/geneseq-emb1/AA1991.DAT\*
- 13: /SID52/qcdata/qcseq/geneseq-emb1/AA1992.DAT\*
- 14: /SID52/qcdata/qcseq/geneseq-emb1/AA1993.DAT\*
- 15: /SID52/qcdata/qcseq/geneseq-emb1/AA1994.DAT\*
- 16: /SID52/qcdata/qcseq/geneseq-emb1/AA1995.DAT\*
- 17: /SID52/qcdata/qcseq/geneseq-emb1/AA1996.DAT\*
- 18: /SID52/qcdata/qcseq/geneseq-emb1/AA1997.DAT\*
- 19: /SID52/qcdata/qcseq/geneseq-emb1/AA1998.DAT\*
- 20: /SID52/qcdata/qcseq/geneseq-emb1/AA1999.DAT\*
- 21: /SID52/qcdata/qcseq/geneseq-emb1/AA2000.DAT\*
- 22: /SID52/qcdata/qcseq/geneseq-emb1/AA2001.DAT\*
- 23: /SID52/qcdata/qcseq/geneseq-emb1/AA2002.DAT\*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

# SUMMARIES

| Result No. | Query Match | Score | Length | ID       | Description         |
|------------|-------------|-------|--------|----------|---------------------|
| 1          | 55          | 100.0 | 11     | AA882039 | Human heprecceptor  |
| 2          | 55          | 100.0 | 12     | AA882038 | Human heprecceptor  |
| 3          | 55          | 100.0 | 13     | AA882037 | Human heprecceptor  |
| 4          | 55          | 100.0 | 14     | AA882036 | Human heprecceptor  |
| 5          | 55          | 100.0 | 436    | AA873954 | Human colon cancer  |
| 6          | 55          | 100.0 | 546    | AA727443 | Amino acid sequence |
| 7          | 55          | 100.0 | 622    | AA030004 | Novel human secret  |
| 8          | 55          | 100.0 | 635    | AA853356 | Human colon cancer  |
| 9          | 47          | 85.5  | 52     | AA033060 | Novel human secret  |
| 10         | 41          | 74.5  | 27     | AA727444 | Actinrapedia inter  |

|    |    |      |      |    |          |                      |
|----|----|------|------|----|----------|----------------------|
| 11 | 40 | 72.7 | 344  | 22 | APG29165 | Novel human diapo    |
| 12 | 39 | 70.9 | 57   | 22 | AB339680 | Peptide #7186 enco   |
| 13 | 39 | 70.9 | 57   | 22 | AA66396  | Human brain expre    |
| 14 | 39 | 70.9 | 57   | 22 | AA673032 | Human bone marrow    |
| 15 | 39 | 70.9 | 57   | 22 | AA633256 | Human peptide enco   |
| 16 | 39 | 70.9 | 57   | 22 | AB42876  | Human peptide enco   |
| 17 | 39 | 70.9 | 429  | 22 | AB19048  | Novel human diapo    |
| 18 | 39 | 70.9 | 429  | 22 | AA74841  | Human colon cancer   |
| 19 | 39 | 70.9 | 802  | 22 | AB19045  | Novel human diapo    |
| 20 | 39 | 70.9 | 2645 | 22 | AB220077 | Novel human diapo    |
| 21 | 37 | 67.3 | 21   | 23 | AB289657 | Insulin/insulin-li   |
| 22 | 36 | 65.5 | 284  | 21 | AA630197 | Arabidopsis thalia   |
| 23 | 36 | 65.5 | 284  | 21 | AA649452 | Arabidopsis thalia   |
| 24 | 36 | 65.5 | 293  | 21 | AA630196 | Arabidopsis thalia   |
| 25 | 36 | 65.5 | 293  | 21 | AA649451 | Arabidopsis thalia   |
| 26 | 36 | 65.5 | 1200 | 21 | AA619413 | Amino acid sequenc   |
| 27 | 35 | 63.6 | 443  | 22 | AB68491  | Drosophila melanog   |
| 28 | 35 | 63.6 | 892  | 22 | AB68491  | Alpha-acl-tic prot   |
| 29 | 34 | 61.8 | 176  | 21 | AA623275 | Arabidopsis thalia   |
| 30 | 34 | 61.8 | 176  | 21 | AA643041 | Arabidopsis thalia   |
| 31 | 34 | 61.8 | 185  | 21 | AA620278 | Arabidopsis thalia   |
| 32 | 34 | 61.8 | 186  | 21 | AA643040 | Arabidopsis thalia   |
| 33 | 34 | 61.8 | 186  | 21 | AA653829 | Arabidopsis thalia   |
| 34 | 34 | 61.8 | 280  | 21 | AA653828 | Arabidopsis thalia   |
| 35 | 34 | 61.8 | 333  | 21 | AA620277 | Arabidopsis thalia   |
| 36 | 34 | 61.8 | 333  | 21 | AA643039 | Arabidopsis thalia   |
| 37 | 34 | 61.8 | 333  | 21 | AA653827 | Arabidopsis thalia   |
| 38 | 34 | 61.8 | 333  | 22 | AB88669  | Rice Photosensitiv   |
| 39 | 34 | 61.8 | 333  | 23 | AA015492 | Beta vulgaris case   |
| 40 | 34 | 61.8 | 333  | 23 | AA652836 | Physcomitrella pat   |
| 41 | 34 | 61.8 | 405  | 11 | AA608119 | CDX, a MILA involy   |
| 42 | 34 | 61.8 | 405  | 12 | AA613552 | GDP Fuc-beta-D-Gal   |
| 43 | 34 | 61.8 | 405  | 12 | AA614454 | Protein 7.2 (1.3-f   |
| 44 | 34 | 61.8 | 405  | 13 | AA628840 | Helicobacter fucosyl |
| 45 | 34 | 61.8 | 405  | 15 | AA645937 | A glycosyltransfer   |

## ALIGNMENTS

|          |  |
|----------|--|
| REFSEQ 1 |  |
| AA882039 |  |
| 15       | AA882039 standard, peptide; 11 AA.   |
| XX       |  |
| AC       | AA882039:  |
| XX       |  |
| ET       | 13-JUN 2501 (first entry)  |
| XX       |  |
| DE       | Human heprecceptor domain A binding peptide Rupe2232.                        |
| XX       |  |
| AW       | Human heprecceptor, cytostatic, anti-HIV; antibiotic;                        |
| KW       | Neutropenic, immune response inducer, anti-HIV; infectious diseases, cancer; |
| KW       | HIV-related dementia.  |
| XX       |  |
| OS       | Homo sapiens.  |
| XX       |  |
| ET       | Key location/qualifiers  |
| ET       | Modified-site 9  |
| ET       | /note- "Optionally phosphorylated"   |
| XX       |  |
| FN       | GB2354241-A.   |
| XX       |  |
| PD       | 21-MAR 2001.   |
| XX       |  |
| ET       | 17 SEP 1999. 99GB 0521881.   |
| XX       |  |
| ET       | 17 SEP 1999. 99GB 0521881.   |
| XX       |  |
| EA       | (HOLM/) HOLMS R.D.   |
| XX       |  |
| PI       | Holms RD;  |
| XX       |  |
| DR       | WFI: 2001 293287/31.   |

XX Novel regulatory or unfolding peptides of ezrin that binds to  
 PT heprecceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer

PS Claim 26; Page 37; 42pp; English.

XX the heprecceptor is a novel active site in human ezrin. Ezrin regulates  
 CC the structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AAB82021 to  
 CC AAB82041) that bind to heprecceptor with greater affinity than HEPI (see  
 CC AAB82046). The heprecceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and  
 CC HIV-related dementia. The present peptide binds to domain A of the  
 CC heprecceptor (AAB82019).

XX Sequence 11 AA;

Query Match 100.0%; Score 55; DB 22; Length 11;  
 Best local Similarity 100.0%; Pred. No. 0.0043;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11  
 ID 1 ELMRLQDYEE 11

RESULT 2

AAB82038  
 ID AAB82038 standard; peptide; 12 AA.

XX AAB82038;

13-JUN-2001 (first entry)

Human heprecceptor domain A binding peptide Rupe2132.

XX Human; heprecceptor; cytostatic; anti-HIV; antibiotic;  
 KW neotropic; immune response inducer; ezrin; infectious diseases; cancer.  
 KW HIV related dementia.

XX Homo sapiens.

XX Key Location/Qualifiers

PT Modified-site 10 /note- "Optionally phosphorylated"

XX GB2354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99GB-0021881.

XX 17-SEP-1999; 99GB-0021881.

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001-293287/41.

XX Novel regulatory or unfolding peptides of ezrin that binds to  
 PT heprecceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer

PS Claim 24; Page 36; 42pp; English.

XX the heprecceptor is a novel active site in human ezrin. Ezrin regulates  
 CC the structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AAB82021 to  
 CC AAB82041) that bind to heprecceptor with greater affinity than HEPI (see  
 CC AAB82046). The heprecceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and

CC HIV related dementia. The present peptide binds to domain A of the  
 CC heprecceptor (AAB82019).

XX Sequence 12 AA;

Query Match 100.0%; Score 55; DB 22; Length 12;  
 Best local Similarity 100.0%; Pred. No. 0.0047;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11  
 ID 2 ELMRLQDYEE 12

RESULT 3

AAB82047  
 ID AAB82047 standard; peptide; 13 AA.

XX AAB82037;

13-JUN-2001 (first entry)

Human heprecceptor domain A binding peptide Rupe2032.

XX Human; heprecceptor; cytostatic; anti-HIV; antibiotic;  
 KW neotropic; immune response inducer; ezrin; infectious diseases; cancer.  
 KW HIV-related dementia.

XX Homo sapiens.

XX Key Location/Qualifiers

PT Modified-site 11 /note- "Optionally phosphorylated"

XX GB2354241-A.

XX 21-MAR-2001.

XX 17-SEP-1999; 99GB-0021881.

XX 17-SEP-1999; 99GB-0021881.

XX (HOLM/) HOLMS R D.

XX Holms RD;

XX WPI: 2001-293287/41.

XX Novel regulatory or unfolding peptides of ezrin that binds to  
 PT heprecceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer

PS Claim 22; Page 36; 42pp; English.

XX the heprecceptor is a novel active site in human ezrin. Ezrin regulates  
 CC the structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AAB82021 to  
 CC AAB82041) that bind to heprecceptor with greater affinity than HEPI (see  
 CC AAB82046). The heprecceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and  
 CC HIV related dementia. The present peptide binds to domain A of the  
 CC heprecceptor (AAB82019).

XX Sequence 13 AA;

Query Match 100.0%; Score 55; DB 22; Length 13;  
 Best local Similarity 100.0%; Pred. No. 0.0051;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11  
 ID 3 ELMRLQDYEE 13

RESULT 4  
 AAB82020  
 ID AAB82020 standard; peptide: 34 AA.  
 XX  
 AC AAB82020;  
 DT 13-JUN-2001 (first entry)  
 DE Human hepreceptor domain B.  
 KW Human: hepreceptor domain B, cytostatic; anti-HIV; antibiotic;  
 KW neotropic; immune response inducer; ezrin; infectious diseases; cancer;  
 KW HIV-related dementia.  
 XX Homo sapiens.  
 FH Key Location/Qualifiers  
 FI Modified-site 14 /note- "Optionally phosphorylated"  
 XX GR2454241-A.  
 XX 21-MAR-2001.  
 PF 17-SEP-1999; 99GR-0021881.  
 PR 17-SEP-1999; 99GR-0021881.  
 PA (HOLM/) HOLMS R D.  
 PI Holms RD;  
 XX WPI: 2001 293287/31  
 XX Novel regulatory or unfolding peptides of ezrin that binds to  
 PT hepreceptor, useful for inducing immune response for treating  
 PT infectious diseases and cancer.  
 XX Claim 5; Page 36; 42pp; English.  
 CC The present sequence is domain B of human hepreceptor of human ezrin. The  
 CC hepreceptor is a novel active site in human ezrin. Ezrin regulates the  
 CC structure of the cortical cytoskeleton to control cell surface  
 CC topography. The present invention relates to peptides (see AAB82021 to  
 CC AAB82041) that bind to hepreceptor with greater affinity than HEP1 (see  
 CC AAB82046). The hepreceptor binding peptides are useful for inducing  
 CC immune response, and for treating infectious diseases, cancer and  
 CC HIV-related dementia. The present sequence assembles into two  
 CC anti-parallel helices with hepreceptor domain A (see AAB82017).  
 SQ Sequence 34 AA;  
 Query Match 100.0%; Score 55; DB 22; Length 34.  
 Best Local Similarity 100.0%; Prod. No. 0.914;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ELMRLQDYEE 11  
 DB 6 ELMRLQDYEE 16  
 RESULT 5  
 AAG73954  
 ID AAG73954 standard; Protein: 436 AA.  
 XX  
 AC AAG73954;  
 DT 03-SEP-2001 (first entry)  
 DE Human colon cancer antigen protein SEQ ID NO:4718.  
 XX Human: colon cancer; colon cancer antigen; diagnosis; detection;  
 KW

KW colorectal carcinoma.  
 XX Homo sapiens.  
 PN WO200122920-A2.  
 XX 05-APR-2001.  
 XX 28-SEP-2000; 2000WO-0526524.  
 PF 29-SEP-1999; 99US-0157137.  
 PR 03-NOV-1999; 99US-0163280.  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 XX Ruben SM, Barash SC, Birse CE, Rosen CA;  
 DE WPI: 2001 235357/24.  
 DR N-PSDH; AAB33385.  
 XX Nucleic acids encoding 4277 human colon cancer-associated polypeptides,  
 PT useful for preventing, diagnosing and/or treating colorectal cancers -  
 XX Claim 11; Page 6520-6521; 9803pp; English.  
 XX AAB32943 to AAB37195 and AAG73514 to AAG77788 represent human colon  
 CC cancer-associated nucleic acid molecules (N) and proteins (P), where  
 CC the proteins are collectively known as colon cancer antigens. The colon  
 CC cancer antigens have cytostatic activity and can be used in gene  
 CC therapy and vaccine production. N and P may be used in the prevention,  
 CC diagnosis and treatment of diseases associated with inappropriate P  
 CC expression. For example, N and P may be used to treat disorders  
 CC associated with decreased expression by rectifying mutations or deletions  
 CC in a patient's genome that affect the activity of P by expressing P  
 CC inactive proteins or to supplement the patient's own production of P.  
 CC Additionally, N may be used to produce the colon cancer-associated PS,  
 CC by inserting the nucleic acids into a host cell and culturing the cell  
 CC to express the proteins. N and P can be used in the prevention, diagnosis  
 CC and treatment of colorectal carcinomas and cancers. AAB37196 to AAB37204  
 CC and AAB77789 represent sequences used in the exemplification of the  
 CC present invention.  
 CC N.B. Gaps 00 to 682 and page 7153 of the sequence listing were  
 CC missing at time of publication, meaning no sequences are present for  
 CC SEQ ID NO:1527 to 1552, 7921 and 7922.  
 XX SQ Sequence 436 AA;  
 Query Match 100.0%; Score 55; DB 22; Length 436;  
 Best Local Similarity 100.0%; Prod. No. 0.18;  
 Matches 11; Conservative 9; Mismatches 9; Indels 0; Gaps 0;  
 QY 1 ELMRLQDYEE 11  
 DB 196 ELMRLQDYEE 206  
 RESULT 6  
 AAY27443  
 ID AAY27443 standard; protein: 586 AA.  
 XX  
 AC AAY27443;  
 XX 26-NOV-1999 (first entry)  
 DE Amino acid sequence of human ezrin polypeptide.  
 KW Pharmaceutical; ezrin; mutant; tumor; metastasis; human.  
 XX Homo sapiens.  
 FH Key Location/Qualifiers  
 FI Misc-difference 354 /note- "the tyr at this position can be mutated  
 FI

PT (preferably to a pHe) to construct an  
 XX ezrin mutant of the invention".  
 PN W0947150-A2.  
 XX  
 XX 23-SEP-1999.  
 XX  
 XX 18-MAR-1999; 99WO-EP02054.  
 XX  
 XX 18-MAR-1998; 98US-0040725.  
 XX  
 XX (COURT-) INST CURIE.  
 XX (CNRS) CNRS CENT NAT RECH SCI.  
 XX  
 XX Arpin M, Crepaldi L, Gauthier A, Louvard D;  
 XX WPI: 1999-561851/47.  
 XX  
 XX New composition for prevention and treatment of tumors and metastasis  
 PT  
 XX  
 XX Example 1: Fig 1: 31pp; English.  
 XX  
 XX The invention provides a pharmaceutical composition containing ezrin  
 CC protein, RNA or DNA mutated on tyrosine 453, or a functional fragment  
 CC or derivative of the ezrin mutant. The new composition is useful for  
 CC prevention and/or treatment of tumors, and especially metastasis. The  
 CC present sequence represents the amino acid sequence of human ezrin  
 CC (before the maturation by deletion of the first amino acid Met).  
 XX  
 XX Sequence 586 AA:  
 SQ  
 Query Match 100.0%; Score 55; DB 20; Length 586;  
 Best Local Similarity 100.0%; Pred. No. 0.25;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ELMLRLQDYEE 11  
 Db 346 ELMLRLQDYEE 456  
 |||||  
 RESULT 7  
 AAU40004  
 ID AAU40004 standard; Protein: 622 AA  
 AC AAU40004;  
 XX  
 XX 18-DEC-2001 (first entry)  
 XX  
 XX Novel human secreted protein #495.  
 XX  
 XX Human; vaccination; gene therapy; nutritional supplement;  
 KW stem cell proliferation; haematopoiesis; nerve tissue regeneration;  
 KW immune suppression; immune stimulation; anti-inflammatory; leukaemia.  
 KW  
 KW Homo sapiens.  
 OS  
 XX W020017449 A2.  
 PN  
 XX 25 OCT 2001.  
 XX  
 XX 16-APR-2001; 2001WO-0508056.  
 XX  
 XX 18-APR-2000; 2000US-0552929.  
 XX 26-JAN-2001; 2001US-0770160.  
 XX  
 XX (HYSEQ) HYSEQ INC.  
 XX  
 XX Tang YL, Liu C, Drmanac R;  
 XX WPI: 2001-611725/76.  
 XX  
 XX Nucleic acids encoding a range of human polypeptides, useful in genetic

PT vaccination, testing and therapy -  
 XX  
 XX Claim 20; Page 219, 765pp; English.  
 XX  
 XX The invention relates to novel human secreted polypeptides. The  
 CC polypeptides and antibodies to the polypeptides are useful for  
 CC determining the presence of or predisposition to a disease associated  
 CC with altered levels of polypeptide. The polypeptides are also useful for  
 CC identifying agents (agonists and antagonists) that bind to them. Cells  
 CC expressing the proteins are useful for identifying a therapeutic agent  
 CC for use in treatment of a pathology related to aberrant expression or  
 CC physiological interactions of the polypeptide. Vectors comprising  
 CC the nucleic acids encoding the polypeptides and cells genetically  
 CC engineered to express them are also useful for producing the proteins.  
 CC The proteins are useful in genetic vaccination, testing and  
 CC therapy, and can be used as nutritional supplements. They may be used to  
 CC increase stem cell proliferation; to regulate haematopoiesis; and in  
 CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;  
 CC immune suppression and/or stimulation; as anti-inflammatory agents; and  
 CC in treatment of leukaemias. AAU29510-AAU33404 represent the amino acid  
 CC sequences of novel human secreted proteins of the invention.  
 XX  
 XX Sequence 622 AA;  
 SQ  
 Query Match 100.0%; Score 55; DB 22; Length 622;  
 Best Local Similarity 100.0%; Pred. No. 0.26;  
 Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;  
 QY 1 ELMLRLQDYEE 11  
 Db 382 ELMLRLQDYEE 392  
 |||||  
 RESULT 8  
 AAB53356  
 ID AAB53356 standard; Protein: 635 AA.  
 AC AAB53356;  
 XX  
 XX 09-MAR-2001 (first entry)  
 XX  
 XX Human colon cancer antigen protein sequence SEQ ID No:896.  
 XX  
 XX Human; colon cancer; colon cancer antigen; diagnosis; detection;  
 KW identification; cytostatic; cardioactive; neuroprotective; vulnecary;  
 KW immunomodulatory; muscular; gynaecological; gastrointestinal;  
 KW nephrotropic; anti-infective; antibacterial; gene therapy; wound;  
 KW neural disorder; immune system disorder; muscular disorder;  
 KW reproductive disorder; gastrointestinal disorder; renal disorder;  
 KW infectious disease; cardiovascular disorder.  
 KW  
 XX Homo sapiens.  
 OS  
 XX W0200055351-A1.  
 PN W0200055351-A1.  
 XX  
 XX 21-SEP-2000.  
 XX  
 XX 08-MAR-2000; 2000WO-0505883.  
 XX  
 XX 12-MAR-1999; 99US-0124270.  
 XX  
 XX (HUMA-) HUMAN GENOME SCI INC.  
 XX  
 XX Rosen CA, Ruben SM;  
 XX WPI: 2000-587534/55.  
 XX N-PSDB; AAC98113.  
 XX  
 XX Colon cancer associated gene sequences, referred to as colon cancer  
 PT antigens, useful for the treatment, prevention, and diagnosis of colon  
 PT disorders such as colon cancer -  
 XX  
 XX Claim 11; Page 1449-1451; 2104pp; English.

XX AAC57991 to AAC98763 encode the human colon cancer associated proteins,  
 CC called human colon cancer antigens, given in AAB53234 to AAB54006. The  
 CC human colon cancer antigens can have cytostatic, cardioactive, muscular,  
 CC neuroprotective, immunomodulatory, gynaecological, gastrointestial, and  
 CC vulvarary, nephrologic, antineoplastic and antibacterial activities, and  
 CC can be used in gene therapy. The colon cancer antigen polynucleotides,  
 CC proteins and antibodies to the proteins are useful for the prevention,  
 CC treatment and diagnosis of colon disorders, such as colon cancer. The  
 CC polynucleotides may be used in diagnostics and research, such as for  
 CC chromosome identification, and as hybridisation probes. The proteins  
 CC may also be used to prevent diseases such as neural disorders, immune  
 CC system disorders, muscular disorders, reproductive disorders,  
 CC gastrointestinal disorders, wounds, renal disorders, infections  
 CC diseases, and cardiovascular disorders. AA598764 to AA598772 and  
 CC AAB54007 represent sequences used in the exemplification of the present  
 CC invention.  
 XX  
 SQ Sequence 635 AA;

Query Match 100.0%; Score 55; DB 21; Length 645;  
 Best Local Similarity 100.0%; Pred No. 0.27;

Matches 11; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11  
 Db 395 ELMRLQDYEE 405

PF00139  
 ID AA033060 standard; Protein: 52 AA.

AC AA033060;

XX 18-DEC-2001 (first entry)

XX Novel human secreted protein #3551.

XX Human; vaccination; gene therapy; nutritional supplement;

XX stem cell proliferation; haematopoiesis; nerve tissue regeneration;

XX immune suppression; immune stimulation; anti-inflammatory; leukaemia.

XX Homo sapiens.

XX WO200179449-A2.

XX 25-OCT-2001.

XX 16-APR-2001; 2001WO-US08656.

XX 18-APR-2000; 2000US-0552929.

XX 26-JAN-2001; 2001US-0770160.

XX (HYSK-) HYSEQ INC.

XX Tang YI, Liu C, Dermanac KI;

XX WPI: 2001-611725/70.

XX Nucleic acids encoding a range of human polypeptides, useful in genetic

XX vaccination, testing and therapy.

XX Claim 20, Page 762, 765pp, English.

XX The invention relates to novel human secreted polypeptides. The

XX polypeptides and antibodies to the polypeptides are useful for

XX determining the presence of or predisposition to a disease associated

XX with altered levels of polypeptides. The polypeptides are also useful for

XX identifying agents (agonists and antagonists) that bind to them. Cells

XX expressing the proteins are useful for identifying a therapeutic agent

XX for use in treatment of a pathology related to aberrant expression or

XX physiological interactions of the polypeptide. Vectors comprising

CC the nucleic acids encoding the polypeptides and cells genetically  
 CC engineered to express them are also useful for producing the proteins.  
 CC The proteins are useful in genetic vaccination, testing and  
 CC therapy, and can be used as nutritional supplements. They may be used to  
 CC increase stem cell proliferation, to regulate haematopoiesis, and in  
 CC bone, cartilage, tendon and/or nerve tissue growth or regeneration;  
 CC immune suppression and/or stimulation, as anti-inflammatory agents, and  
 CC in treatment of leukaemias. AA029510 AA033064 represent the amino acid  
 CC sequences of novel human secreted proteins of the invention.

SQ Sequence 52 AA;

Query Match 85.5%; Score 47; DB 22; Length 52;

Best Local Similarity 90.4%; Pred No. 0.49;

Matches 10; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMRLQDYEE 11

Db 14 ELMRLQDYEE 24

RESULT 10

AAV27444

ID AAY27444 standard; peptide: 27 AA.

XX AAY27444;

XX 26-NOV-1999 (first entry)

XX Antennapedia internalization sequence in tandem with ezrin fragment.

XX Pharmaceutical, ezrin, mutant, tumor, antennapedia internalization;

XX metastasis; human.

XX Synthetic.

XX KEY Location/Qualifiers

FT Modified-site 1 /note= "biotinylated"

FT Modified site 22

FT /note= "optionally phosphorylated"

XX W09947150-A2.

XX 23-SEP-1999.

XX 18-MAR-1999; 99WO-EP02054.

XX 18-MAR-1998; 98US-0040725.

XX (CURI-) INST CURIE.

XX (CRES) CRES CENT NAT RECH SCI.

XX Arpin M, Crepaldi T, Gautreau A, Louvard D;

XX WPI: 1999-561851/47.

XX New composition for prevention and treatment of tumors and metastasis

XX Example 5; Page 14; 31pp; English.

XX The invention provides a pharmaceutical composition containing ezrin

XX protein, RNA or DNA mutated on tyrosine 353, or a functional fragment

XX or derivative of the ezrin mutant. The new composition is useful for

XX prevention and/or treatment of tumors, and especially metastasis. The

XX present sequence represents an antennapedia internalization sequence in

XX tandem with an ezrin fragment (residues 348-358). This is used in

XX experiments of p85 interaction with phosphorylated ezrin peptides.

SQ Sequence 27 AA;

Query Match 74.5%; Score 41; DB 20; Length 27;

Best Local Similarity 100.0%; Pred. No. 2.7;  
Matches 8; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 4 ELMLRLQDYE 11  
IIIIII IIII  
DB 17 ELMLRLQDYE 24

RESULT 11  
AAG29165  
ID AAG29165 standard; Protein: 44 AA.

XX AC AAG29165;  
XX DT 13-FEB-2002 (first entry)

XX DE Novel human diagnostic protein #29156.

XX KW Human; chromosome mapping; gene mapping; gene therapy; forensic;  
XX RW food supplement; medical imaging; diagnostic; genetic disorder.

XX OS Homo sapiens.

XX PN W0200175067-A2.

XX PD 11-OCT-2001.

XX PF 30-MAR-2001; 2001W0-0509631.

XX PR 31-MAR-2000; 2000US-0540117.

XX PP 23-APR-2000; 2000US-0649167.

XX PA (HYSE) HYSEQ INC.

XX PI Drmanac RT, Liu C, Tang YL;

XX DR WPI; 2001-649462/73.

XX DR N-PSDB; AAS9452.

XX PT New isolated polynucleotide and encoded polypeptides, useful in  
diagnostics, forensics, gene mapping, identification of mutations  
responsible for genetic disorders or other traits and to assess  
biodiversity.

XX PS Claim 20; SEQ ID NO 59524; 101pp; English.

XX CC The invention relates to isolated polynucleotide (I) and  
polypeptide (II) sequences. (I) is useful as hybridisation probes,  
polymerase chain reaction (PCR) primers, oligomers, and for chromosome  
and gene mapping, and in recombinant production of (II). The  
polynucleotides are also used in diagnostics as expressed sequence tags  
for identifying expressed genes. (I) is useful in gene therapy techniques  
to restore normal activity of (I) or to treat disease states involving  
(II). (II) is useful for generating antibodies against it, detecting or  
quantitating a polypeptide in tissue, as molecular weight markers and as  
a food supplement. (II) and its binding partners are useful in medical  
imaging of sites expressing (II). (I) and (II) are useful for treating  
disorders involving aberrant protein expression or biological activity.  
The polypeptide and polynucleotide sequences have applications in  
diagnostics, forensics, gene mapping, identification of mutations  
responsible for genetic disorders or other traits to assess biodiversity  
and to produce other types of data and products dependent on DNA and  
amino acid sequences. AAG00010-AAG00017 represent novel human  
diagnostic amino acid sequences of the invention.

XX CC Note: The sequence data for this patent did not appear in the printed  
specification, but was obtained in electronic format directly from WIPO  
at [http://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences).

XX SQ Sequence 44 AA;

Query Match 72.7%; Score 49; DB 22; Length 344;  
Best Local Similarity 80.0%; Pred. No. 53;  
Matches 8; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMLRLQDYE 10  
IIIIII IIII  
DB 279 ELMLRLQDYE 288

RESULT 12

ABB39680  
ID ABB39680 standard; Peptide: 57 AA.

XX AC ABB39680;

XX DT 04-FEB-2002 (first entry)

XX DE Peptide #7186 encoded by human foetal liver single exon probe.

XX KW Human; foetal liver; gene expression; single exon nucleic acid probe.

XX OS Homo sapiens.

XX PN W0200157277-A2.

XX PD 09-AUG-2001.

XX PF 30-JAN-2001; 2001W0-0500669.

XX PR 04-FEB-2000; 2000US-0180312.

XX PR 26-MAY-2000; 2000US-0207456.

XX PR 30-JUN-2000; 2000US-0608408.

XX PR 03-AUG-2000; 2000US-0632366.

XX PR 21-SEP-2000; 2000US-0234687.

XX PP 27-SEP-2000; 2000US-0236359.

XX PR 04-OCT-2000; 2000US-0024263.

XX PA (MOLEC) MOLECULAR DYNAMICS INC.

XX PI Penn SG, Hanzel DK, Chen W, Rank DR;

XX DR WPI; 2001-483447/52.

XX PT Human genome-derived single exon nucleic acid probes useful for  
analyzing gene expression in human foetal liver.

XX PS Claim 27; SEQ ID NO 32315; 639pp + sequence listing; English.

XX CC The invention relates to a single exon nucleic acid probe for  
measuring human gene expression in a sample derived from human foetal  
liver. The single exon nucleic acid probes may be used for predicting,  
measuring and displaying gene expression in samples derived from human  
foetal liver. The present sequence is a peptide encoded by a single exon  
nucleic acid probe of the invention.

XX CC Note: The sequence data for this patent did not form part of the  
printed specification, but was obtained in electronic format directly  
from WIPO at [http://wipo.int/pub/published\\_pct\\_sequences](http://wipo.int/pub/published_pct_sequences).

XX SQ Sequence 57 AA;

Query Match 70.9%; Score 39; DB 22; Length 57;  
Best Local Similarity 72.7%; Pred. No. 11;  
Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMLRLQDYE 11  
IIIIII IIII  
DB 18 ELMLRLQDYE 28

RESULT 13

AAM60396  
ID AAM60396 standard; Protein: 57 AA.

XX AC AAM60396;

XX DT 05-NOV-2001 (first entry)



Pl Human genome derived single exon nucleic acid probes useful for  
 pr analyzing gene expression in human placenta -  
 XX  
 PS Claim 27: SEQ ID No 33525: 654bp; English.  
 XX  
 cc the present invention relates to single exon nucleic acid probes (SENPs;  
 cc see AA131315-AA157546). The present sequence is a peptide encoded by one  
 cc such probe. The probes are useful for producing a microarray for  
 cc predicting, measuring and displaying gene expression in samples derived  
 cc from human placenta. The probes are useful for antenatal diagnosis of  
 cc human genetic disorders.

XX Sequence 57 AA:

Query Match 70.9%; Score 49; DB 22; Length 57;  
 Best Local Similarity 72.7%; Pred. No. 13;  
 Matches 8; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 1 ELMLRLQVYER 11  
 II:IIII:II  
 Db 18 ELILLRLQVYEF 28

Search completed: January 16, 2003, 16:49:15  
 Job time : 52.3286 secs